Cost Effectiveness of Romiplostim for the Treatment of Immune Thrombocytopenia (Itp) Patients In the Czech Republic

Value Health. 2014 Nov;17(7):A533. doi: 10.1016/j.jval.2014.08.1696. Epub 2014 Oct 26.

Authors

T Brezina¹, J Klimes², T Dolezal², H Maskova¹, M Campioni³, L Kutikova³

Affiliations

¹ Amgen s. r. o., Praha 1, Czech Republic.
² VALUE OUTCOMES, Prague, Czech Republic.
³ Amgen (Europe) GmbH, Zug, Switzerland.

PMID: 27201699
DOI: 10.1016/j.jval.2014.08.1696

No abstract available